CareDx agreed to acquire Naveris for up to $260 million to expand its precision oncology diagnostics offering. The deal provides CareDx access to NavDx, a liquid biopsy test that detects viral DNA fragments tied to HPV-driven cancers. CareDx said NavDx received Medicare coverage in 2023 and is positioned as a tumor-naïve minimal residual disease (MRD) tool for ongoing molecular monitoring in HPV-related malignancies. Naveris operates high-complexity clinical laboratories in Massachusetts and North Carolina and reported 2025 unaudited revenue of $34 million. Management said the acquisition is intended as a targeted addition within a viral-mediated oncology niche where longitudinal monitoring is already reimbursed and embedded into specialty workflows. For diagnostic companies, the transaction underscores how MRD and liquid biopsy adoption is consolidating into larger platforms with established reimbursement pathways and lab operating scale.